Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...
RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...
The intestinal epithelium undergoes rapid renewal every 3–5 days, a process driven by intestinal stem cells (ISCs) located at ...
The latest announcement is out from Nucana ( (NCNA) ).
NICE Actimize, a NiCE business, today announced that it has been recognized as a Leader in Enterprise Fraud Management ...
EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on improving treatment outcomes ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...
Modern Engineering Marvels on MSN
Smaller than salt: Microrobots poised to transform medicine
Building robots that operate independently at sizes below one millimeter is incredibly difficult,” it is exceedingly hard to ...
NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for ...
Eastman Kodak faces secular decline in print as digital media erodes demand for its core printing plate business. Read why ...
In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback